AOD-9604 Pediatric (Under 12) Monitoring: What Clinicians Need to Know

What Is AOD-9604 and Why Is Pediatric Use a Concern?

AOD-9604 is a synthetic peptide derived from amino acids 176 to 191 of human growth hormone. It was designed to retain the lipolytic activity of the parent molecule without triggering GH-receptor-mediated IGF-1 secretion. That receptor selectivity was first characterized in animal models by Heffernan et al. In 2001, who demonstrated that the fragment stimulated fat breakdown through beta-3 adrenergic pathways rather than through classic somatotropic signaling 1.

Children under 12 present a categorically different risk profile from adults. The prepubertal skeleton has open growth plates. The hypothalamic-pituitary-GH axis is in active developmental flux. Adipose tissue distribution differs substantially from adult patterns, and the consequences of even modest hormonal perturbation during this window can extend decades into adulthood.

Why Clinicians Are Seeing Pediatric Requests

Parental interest in AOD-9604 for children typically centers on weight management in pediatric obesity, a condition affecting roughly 19.7% of U.S. Children aged 2 to 19 years according to CDC NHANES data 2. That prevalence creates demand for novel agents, but demand does not equal evidence. No phase II or phase III trial of AOD-9604 has been conducted in any pediatric population.

FDA Regulatory Framework for Pediatric Peptides

The FDA has not approved AOD-9604 for any indication in any age group. The agency's 2023 guidance on bulk drug substances for compounding lists AOD-9604 on the Category 2 list, meaning it lacks adequate clinical evidence of safety and efficacy 3. Prescribing it to a child under 12 places the clinician entirely outside any regulatory safety net. The Pediatric Research Equity Act (PREA) requires sponsors seeking adult approval to study drugs in pediatric populations, but because AOD-9604 never reached adult approval, PREA pediatric data requirements were never triggered 4.

Growth and Skeletal Monitoring Protocols

Growth velocity is the single most important continuous biomarker to track in any child receiving an experimental peptide. Children under 12 grow at an average of 5 to 6 cm per year during mid-childhood, with acceleration expected near puberty onset 5. Any deviation from the established growth curve warrants immediate peptide discontinuation and endocrinology referral.

Anthropometric Measurements

At every monitoring visit, clinicians must record:

• Standing height measured with a calibrated stadiometer (not a wall tape)
• Weight and BMI-for-age percentile using CDC 2000 growth charts 6
• Mid-upper arm circumference and waist circumference as secondary adiposity markers
• Tanner stage assessment, because pubertal onset shifts the hormonal context entirely

Height velocity should be plotted on a height-velocity chart at every 6-month interval. A decline of more than 25% from the child's pre-treatment velocity is a red-flag threshold requiring endocrine workup.

Bone Age Radiography

A left-hand and wrist X-ray for bone age (Greulich-Pyle method) should be obtained at baseline and repeated every 12 months 7. Bone age advancement beyond 2 standard deviations of chronological age suggests androgen or growth factor excess and is grounds for stopping AOD-9604 immediately.

The rationale is straightforward. AOD-9604 does not activate the GH receptor in animal models 1, but children have a more permeable hormonal environment. Off-target effects that are clinically silent in adults could accelerate epiphyseal fusion in a 9-year-old, permanently limiting adult stature.

Endocrine and IGF-1 Monitoring

Baseline Endocrine Panel

Before any AOD-9604 prescription is written for a child under 12, a complete baseline endocrine panel is non-negotiable. This panel should include:

• IGF-1 and IGFBP-3 (age- and sex-matched Z-scores)
• Fasting growth hormone stimulation testing if baseline IGF-1 is below -2 SD
• Thyroid function: TSH, free T4
• Morning cortisol and ACTH if adrenal insufficiency is in the differential
• LH, FSH, and estradiol or testosterone if early pubertal signs are present

The Endocrine Society's 2016 clinical practice guideline on pediatric growth hormone deficiency recommends IGF-1 Z-scores as the primary biochemical monitoring tool throughout any GH-axis-related therapy 8. AOD-9604 theoretically should not raise IGF-1 because it bypasses the GH receptor, but no pediatric human data confirm this.

Follow-Up Endocrine Testing Schedule

| Timepoint | IGF-1 / IGFBP-3 | Thyroid Panel | Morning Cortisol | |-----------|----------------|---------------|-----------------| | Baseline | Yes | Yes | Yes | | 3 months | Yes | No | Only if symptomatic | | 6 months | Yes | Yes | Only if symptomatic | | 12 months | Yes | Yes | Yes | | Annually thereafter | Yes | Yes | Yes |

Any IGF-1 Z-score rise above +2 SD from baseline warrants a 4-week washout period and repeat testing before re-dosing is considered.

Glycemic and Metabolic Monitoring

AOD-9604's proposed metabolic mechanism includes beta-3 adrenergic receptor activation and possible insulin-sensitizing effects observed in animal lipolysis studies 1. In adults, this may be benign or mildly beneficial, but prepubertal children already have heightened insulin sensitivity compared to pubertal adolescents 9. The interaction between a peptide with theoretical insulin-modulating properties and a child's baseline physiology is entirely unstudied.

Glycemic Markers to Track

• Fasting plasma glucose at baseline and every 3 months
• HbA1c at baseline and every 6 months
• Fasting insulin and HOMA-IR calculation at baseline and every 6 months
• A lipid panel (total cholesterol, LDL, HDL, triglycerides) at baseline and every 12 months

The American Diabetes Association's Standards of Medical Care in Diabetes 2024 recommend HbA1c and fasting glucose as the primary screening tools for pediatric dysglycemia in overweight or obese children, using a threshold of HbA1c 5.7% to flag prediabetes 10. Any child whose HbA1c crosses 5.7% while on AOD-9604 should have the peptide held and formal diabetes specialist evaluation initiated.

Cardiovascular Considerations

Pediatric obesity is independently associated with early atherosclerosis and left ventricular hypertrophy 11. A blood pressure measurement at every monitoring visit is mandatory. Resting heart rate trends should also be recorded because beta-3 adrenergic stimulation theoretically could affect cardiac chronotropy in susceptible children.

Dosing Considerations: No Pediatric Dose Is Established

No weight-based or age-adjusted pediatric dose for AOD-9604 exists in any published literature or regulatory document. Adult compounding protocols typically use 250 to 500 mcg subcutaneously once daily. Applying adult doses to a 30-kg child under 12 produces a per-kilogram exposure 2 to 3 times higher than in a 75-kg adult using the same absolute dose. That exposure gap is clinically meaningful.

Allometric Scaling Principles

The FDA's guidance on pediatric dose selection recommends allometric scaling using the exponent 0.75 for drugs with predominantly renal or hepatic clearance, expressed as: Pediatric dose = Adult dose x (Child weight / 70 kg)^0.75 12. Applied to a 30-kg child, this formula yields approximately 58% of the adult dose, or roughly 145 to 290 mcg per day from an adult range of 250 to 500 mcg. This is a mathematical starting point only, not a clinical recommendation, because the pharmacokinetics of AOD-9604 in children have never been studied.

Injection Site Rotation in Children

Subcutaneous injection in children under 12 requires special attention to injection site selection. The abdomen, anterior thigh, and upper arm are standard sites for pediatric subcutaneous therapy per American Academy of Pediatrics guidance on insulin injection in children 13. Site rotation charts should be provided at every visit to prevent lipodystrophy, which can confound interpretation of adiposity changes attributed to the peptide.

Hepatic and Renal Safety Surveillance

Peptide clearance in children under 12 relies on renal filtration and hepatic peptidase activity, both of which differ quantitatively from adult parameters. Glomerular filtration rate per body surface area is actually higher in children aged 2 to 12 than in adults, reaching approximately 127 mL/min/1.73m2 by age 2 and remaining stable through mid-childhood 14. Higher GFR means faster renal clearance, which may reduce systemic exposure relative to adults at the same dose, but it provides no protection against organ-specific toxicity.

Recommended Lab Panel

• Comprehensive metabolic panel (CMP) including ALT, AST, alkaline phosphatase, creatinine, and BUN at baseline and every 6 months
• Urinalysis with microscopy at baseline and every 12 months
• ALT above 3x the upper limit of normal for age requires immediate peptide discontinuation 15

Alkaline phosphatase in growing children is physiologically elevated due to osteoblast activity and should not be misinterpreted as hepatic injury. Age-specific reference ranges must be used 16.

Informed Consent and Ethical Obligations

Prescribing an unapproved, unvalidated compound to a patient who cannot legally consent for themselves creates layered ethical obligations. The American Academy of Pediatrics policy on off-label drug use states that clinicians must disclose the investigational nature of the therapy, the absence of pediatric safety data, and all alternatives including approved pharmacotherapy 17.

For AOD-9604 in under-12 patients, a written informed consent document signed by both parents or legal guardians (where feasible) should include:

• A statement that no pediatric clinical trials have been conducted
• A description of all known adult adverse effects from available compounding literature
• An explicit acknowledgment that long-term growth and endocrine effects are unknown
• A clear discontinuation plan with specific trigger criteria

The HealthRX Pediatric Peptide Monitoring Framework defines three decision tiers. Tier 1 (Green) is defined by stable growth velocity within 25% of pre-treatment baseline, IGF-1 Z-score within -1 to +1 SD of baseline, HbA1c below 5.7%, and no adverse events. Tier 2 (Yellow) is defined by growth velocity decline of 25 to 40% from baseline, OR IGF-1 Z-score shift beyond +1.5 SD, OR fasting glucose 100 to 125 mg/dL. Tier 1 continues current dose with standard monitoring. Tier 2 requires dose reduction by 50%, repeat labs in 6 weeks, and mandatory pediatric endocrinology co-management. Tier 3 (Red) is defined by growth velocity decline greater than 40% from baseline, OR IGF-1 Z-score above +2 SD, OR HbA1c at or above 5.7%, OR any hepatic enzyme above 3x upper limit of normal. Tier 3 requires immediate peptide discontinuation and urgent specialist referral.

Alternatives to AOD-9604 for Pediatric Weight Management

Before initiating any experimental compound in a child under 12, clinicians should have exhausted evidence-based options. The American Academy of Pediatrics 2023 clinical practice guideline on obesity in children and adolescents recommends intensive health behavior and lifestyle treatment (IHBLT) as the first-line intervention, offering at least 26 contact hours in the first 3 to 12 months 18. For children aged 8 and older with BMI at or above the 95th percentile and comorbidities, metformin may be considered as an adjunct, and FDA-approved pharmacotherapy (orlistat for ages 12 and up) is available 19. No GLP-1 receptor agonist currently carries FDA approval for weight management below age 12. Semaglutide (Wegovy) is approved for adolescents aged 12 and older based on the STEP TEENS trial (N=201), which showed 16.1% mean BMI reduction at 68 weeks versus 0.6% with placebo 20.

AOD-9604 sits below every one of those approved options on the evidence ladder. Its use in children under 12 should be reserved for cases where all guideline-supported interventions have failed, a compelling clinical rationale exists, and a structured monitoring protocol is actively in place.

Reporting Adverse Events

Any clinician prescribing AOD-9604 to a child under 12 has a professional obligation to report adverse events through FDA MedWatch 21. Compounding pharmacies dispensing the product under 503A rules are also subject to adverse event reporting requirements under 21 CFR Part 310 22. Clinicians should document every adverse event in the medical record with date, severity grade per the CTCAE v5.0 scale 23, and the clinical response taken.

Collecting and sharing this data, even as case reports, is the only way the field will eventually develop the evidence base this population currently lacks.